Cyclin A2 confers cisplatin resistance to endometrial carcinoma cells via up-regulation of an Akt-binding protein, periplakin

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 9, 2010, Pages 2305-2317

  Suzuki, Akihisa ^a   Horiuchi, Akiko ^a   Ashida, Takashi ^a   Miyamoto, Tsutomu ^a   Kashima, Hiroyasu ^a   Nikaido, Toshio ^b   Konishi, Ikuo ^c   Shiozawa, Tanri ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Cyclin A2; Endometrial carcinoma; Periplakin; PI3K

Indexed keywords

CISPLATIN; CYCLIN A2; PHOSPHATIDYLINOSITOL 3 KINASE; PLAKIN; PPL PROTEIN, HUMAN; PROTEIN KINASE B; TRANSCRIPTION FACTOR SP1;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BINDING SITE; CELL PROLIFERATION; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; ENDOMETRIUM TUMOR; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROMOTER REGION; PROTEIN BINDING; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN A2; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PLAKINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 78649377123     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00839.x     Document Type: Article

References (38)

1. Girard F, Strausfeld U, Fernandez A, et al. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991; 67: 1169-79.
2. Dobashi Y, Shoji M, Jiang SX, et al. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol. 1998; 153: 963-72.
3. Chao Y, Shih YL, Chiu JH, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 1998; 58: 985-90.
4. Mrena J, Wiksten JP, Kokkola A, et al. Prognostic significance of cyclin A in gastric cancer. Int J Cancer. 2006; 119: 1897-901.
5. Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumorsuppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol. 2003; 34: 471-8.
6. Muller-Tidow C, Ji P, Diederichs S, et al. The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol. 2004; 24: 8917-28.
7. Hsieh JK, Yap D, O'Connor DJ, et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol. 2002; 22: 78-93.
8. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008; 108: 226-33.
9. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22: 7265-79.
10. Yang X, Fraser M, Moll UM, et al. Aktmediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 2006; 66: 3126-36.
11. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002; 1: 707-17.
12. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997; 57: 3935-40.
13. Shiozawa T, Miyamoto T, Kashima H, et al. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene. 2004; 23: 8603-10.
14. Wang CH, Chang HC, Hung WC. p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J Cell Physiol. 2006; 208: 246-52.
15. Casalino L, Bakiri L, Talotta F, et al. Fra-1 promotes growth and survival in RAStransformed thyroid cells by controlling cyclin A transcription. EMBO J. 2007; 26: 1878-90.
16. Tsai SJ, Wu MH, Chen HM, et al. Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology. 2002; 143: 2715-21.
17. Chau BN, Cheng EH, Kerr DA, et al. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell. 2000; 6: 31-40.
18. Kleivi K, Lind GE, Diep CB, et al. Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer. 2007; 6: 2.
19. Chano T, Ikegawa S, Kontani K, et al. Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene. 2002; 21: 1295-98.
20. Memarzadeh S, Kozak KR, Chang L, et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci U S A. 2002; 99: 10647-52.
21. van den Heuvel AP, de Vries-Smits AM, van Weeren PC, et al. Binding of protein kinase B to the plakin family member periplakin. J Cell Sci. 2002; 115: 3957-66.
22. Schug TT, Berry DC, Shaw NS, et al. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007; 129: 723-33.
23. Ahn MY, Katsanakis KD, Bheda F, et al. Primary and essential role of the adaptor protein APS for recruitment of both c-Cbl and its associated protein CAP in insulin signaling. J Biol Chem. 2004; 279: 21526-32.
24. Jain A, Tindell CA, Laux I, et al. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005; 102: 11858-63.
25. Yeung HY, Lai KP, Chan HY, et al. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology. 2005; 146: 4951-60.
26. Christakos S, Liu Y. Biological actions and mechanism of action of calbindin in the process of apoptosis. J Steroid Biochem Mol Biol. 2004; 89-90: 401-4.
27. Aho S, Rothenberger K, Tan EM, et al. Human periplakin: genomic organization in a clonally unstable region of chromosome 16p with an abundance of repetitive sequence elements. Genomics. 1999; 56: 160-8.
28. Banchio C, Schang LM, Vance DE. Phosphorylation of Sp1 by cyclin-dependent kinase 2 modulates the role of Sp1 in CTP: phosphocholine cytidylyltransferase alpha regulation during the S phase of the cell cycle. J Biol Chem. 2004; 279: 40220-6.
29. Fojas de Borja P, Collins NK, Du P, et al. Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J. 2001; 20: 5737-47.
30. Haidweger E, Novy M, Rotheneder H. Modulation of Sp1 activity by a cyclin A/CDK complex. J Mol Biol. 2001; 306: 201-12.
31. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994; 57: 847-55.
32. Bedrosian I, Lee C, Tucker SL, et al. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007; 13: 4800-6.
33. Gagnon V, Mathieu I, Sexton E, et al. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004; 94: 785-95.
34. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signalregulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000; 60: 5988-94.
35. Owen GI, Richer JK, Tung L, et al. Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998; 273: 10696-701.
36. Barthel R, Tsytsykova AV, Barczak AK, et al. Regulation of tumor necrosis factor alpha gene expression by mycobacteria involves the assembly of a unique enhanceosome dependent on the coactivator proteins CBP/p300. Mol Cell Biol. 2003; 23: 526-33.
37. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24: 1770-83.
38. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003; 3: 233-45.